Four years af­ter near-death ex­pe­ri­ence, PhI­II da­ta bring good news for No­vavax

No­vavax is cel­e­brat­ing tri­al re­sults again four years af­ter a Phase III fail­ure in RSV sent their stock price off a cliff.

The com­pa­ny an­nounced …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.